Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HPGDS | O60760 | 4/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26681960 | 0.90 | MAOB (0.61) | MAOBALDH1A1HPGDKDM4EPDGFRB | |
| SCHEMBL1040763 | 0.89 | MAOB (0.80) | MAOBHPGDS | |
| Hydrochloric Acid SCHEMBL6312857 | 0.88 | MAOB (0.78) | MAOBHPGDS | |
| SCHEMBL28782953 | 0.88 | MAOB (0.56) | MAOBALDH1A1HPGDKDM4EF2 | |
| SCHEMBL20799517 | 0.86 | ALDH1A1 (0.62) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL28701482 | 0.86 | MAOB (0.57) | MAOBALDH1A1HPGDKDM4EHPGDS | |
| SCHEMBL29365635 | 0.86 | MAOB (0.57) | MAOBALDH1A1HPGDKDM4EHPGDS | |
| SCHEMBL26680685 | 0.83 | MAOB (0.56) | MAOBALDH1A1KDM4EPDGFRBPDGFRA | |
| SCHEMBL29793278 | 0.83 | MAOB (0.56) | MAOBALDH1A1KDM4EPDGFRBPDGFRA | |
| SCHEMBL4398696 | 0.82 | MAOB (0.56) | MAOBALDH1A1KDM4EPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227355-B2 | Quinoline derivatives and preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-03-12 | — | — | US | disclosed |
| US-20180237448-A1 | NOVEL QUINOLINE DERIVATIVES AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-08-23 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| CN-100537540-C | Process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2009-09-09 | — | — | CN | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| US-5639885-A | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0293071-B1 | REDOX AMINO ACIDS AND PEPTIDES CONTAINING THEM | UNIVERSITY OF FLORIDA (US) | 1993-09-01 | — | — | EP | disclosed |
| US-5079366-A | To derivatize pharmaceutical peptides for transport across the blood/brain barrier | UNIVERSITY OF FLORIDA (US) | 1992-01-07 | — | — | US | disclosed |
| US-4888427-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX SYSTEM | UNIVERSITY OF FLORIDA (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0293071-A1 | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237448-A1 | NOVEL QUINOLINE DERIVATIVES AND PREPARATION THEREOF | ABL1, FLT3, MAP3K7 | MAOB 478/4885ALDH1A1 1992/4885HPGD 1637/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | MAOB 902/4885ALDH1A1 81/4885HPGD 150/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | MAOB 1017/4885ALDH1A1 433/4885HPGD 165/4885 |
| US-10227355-B2 | Quinoline derivatives and preparation thereof | ABL1, FLT3, MAP3K7 | MAOB 380/4885ALDH1A1 2096/4885HPGD 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.